Lexicon Pharmaceuticals (LXRX) Competitors $0.57 +0.01 (+2.55%) Closing price 05/20/2025 04:00 PM EasternExtended Trading$0.57 0.00 (-0.53%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXRX vs. GERN, RGLS, ZBIO, MYGN, VSTM, RIGL, EBS, XOMA, VNDA, and CDXSShould you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Geron (GERN), Regulus Therapeutics (RGLS), Zenas Biopharma (ZBIO), Myriad Genetics (MYGN), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), and Codexis (CDXS). These companies are all part of the "biotechnology" industry. Lexicon Pharmaceuticals vs. Geron Regulus Therapeutics Zenas Biopharma Myriad Genetics Verastem Rigel Pharmaceuticals Emergent BioSolutions XOMA Vanda Pharmaceuticals Codexis Lexicon Pharmaceuticals (NASDAQ:LXRX) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership. Do analysts prefer LXRX or GERN? Lexicon Pharmaceuticals presently has a consensus target price of $3.67, indicating a potential upside of 543.27%. Geron has a consensus target price of $5.06, indicating a potential upside of 264.21%. Given Lexicon Pharmaceuticals' higher probable upside, research analysts plainly believe Lexicon Pharmaceuticals is more favorable than Geron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexicon Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Geron 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.78 Do institutionals & insiders hold more shares of LXRX or GERN? 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 4.5% of Lexicon Pharmaceuticals shares are owned by company insiders. Comparatively, 7.4% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community favor LXRX or GERN? Geron received 16 more outperform votes than Lexicon Pharmaceuticals when rated by MarketBeat users. Likewise, 69.93% of users gave Geron an outperform vote while only 64.02% of users gave Lexicon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformLexicon PharmaceuticalsOutperform Votes48464.02% Underperform Votes27235.98% GeronOutperform Votes50069.93% Underperform Votes21530.07% Does the media refer more to LXRX or GERN? In the previous week, Lexicon Pharmaceuticals had 5 more articles in the media than Geron. MarketBeat recorded 14 mentions for Lexicon Pharmaceuticals and 9 mentions for Geron. Geron's average media sentiment score of 0.91 beat Lexicon Pharmaceuticals' score of 0.63 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is LXRX or GERN more profitable? Geron has a net margin of -682.48% compared to Lexicon Pharmaceuticals' net margin of -4,109.41%. Geron's return on equity of -67.53% beat Lexicon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lexicon Pharmaceuticals-4,109.41% -107.38% -64.09% Geron -682.48%-67.53%-45.46% Which has more volatility & risk, LXRX or GERN? Lexicon Pharmaceuticals has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Which has preferable earnings and valuation, LXRX or GERN? Lexicon Pharmaceuticals has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexicon Pharmaceuticals$31.21M6.60-$177.12M-$0.51-1.12Geron$116.29M7.61-$184.13M-$0.21-6.62 SummaryGeron beats Lexicon Pharmaceuticals on 13 of the 19 factors compared between the two stocks. Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXRX vs. The Competition Export to ExcelMetricLexicon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$200.92M$6.54B$5.43B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.769.1426.7920.05Price / Sales6.60255.59394.72116.44Price / CashN/A65.8538.2534.62Price / Book1.506.546.864.61Net Income-$177.12M$143.51M$3.22B$248.19M7 Day Performance7.16%5.60%6.83%2.97%1 Month Performance-0.87%10.06%13.73%16.58%1 Year Performance-65.87%-0.86%18.22%8.16% Lexicon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXRXLexicon Pharmaceuticals3.2436 of 5 stars$0.57+2.6%$3.67+543.3%-67.8%$200.92M$31.21M-0.76140GERNGeron4.1657 of 5 stars$1.29+8.9%$5.06+294.0%-62.7%$812.07M$116.29M-3.9870RGLSRegulus Therapeutics1.3373 of 5 stars$7.87-0.1%$8.50+8.1%+295.5%$521.00MN/A-7.3530Analyst ForecastZBIOZenas BiopharmaN/A$9.80+8.3%$40.00+308.2%N/A$409.97M$5M-2.76N/ATrending NewsEarnings ReportAnalyst RevisionGap UpMYGNMyriad Genetics4.1131 of 5 stars$4.18+7.3%$16.04+284.1%-82.2%$384.75M$837.60M-3.212,600Gap UpVSTMVerastem3.176 of 5 stars$7.06-1.5%$14.33+102.9%-30.8%$366.09M$10M-2.2350Insider TradeRIGLRigel Pharmaceuticals2.8616 of 5 stars$18.46-1.7%$36.40+97.2%+110.7%$329.29M$179.28M131.65160Positive NewsEBSEmergent BioSolutions4.4785 of 5 stars$5.91+4.5%$14.33+142.7%+19.7%$320.32M$1.01B-1.442,420Analyst RevisionXOMAXOMA4.1785 of 5 stars$24.82+2.6%$69.50+180.1%+6.3%$296.61M$10.22M-7.1310News CoverageInsider TradeAnalyst RevisionGap UpVNDAVanda Pharmaceuticals4.4247 of 5 stars$4.07+2.9%$16.50+305.9%-15.7%$239.57M$198.77M-12.70290CDXSCodexis3.4097 of 5 stars$2.61+5.9%$8.00+207.1%-27.9%$215.81M$59.35M-2.99250Positive NewsEarnings ReportAnalyst RevisionGap Up Related Companies and Tools Related Companies GERN Alternatives RGLS Alternatives ZBIO Alternatives MYGN Alternatives VSTM Alternatives RIGL Alternatives EBS Alternatives XOMA Alternatives VNDA Alternatives CDXS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LXRX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LXRX Stock Free LXRX Stock Alerts